# Secukinumab in Tumor Necrosis Factor (TNF) - Inadequate Response (IR) Psoriasis Participants.

> **NCT01961609** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 235 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **BIOLOGICAL:** Secukinumab (AIN457)

## Key facts

- **NCT ID:** NCT01961609
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-09
- **Primary completion:** 2016-07-12
- **Final completion:** 2016-07-12
- **Target enrollment:** 235 (ACTUAL)
- **Last updated:** 2019-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01961609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01961609, "Secukinumab in Tumor Necrosis Factor (TNF) - Inadequate Response (IR) Psoriasis Participants.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01961609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*